Monday, August 24
Danish pharmaceutical giant Novo Nordisk announced Monday the US Food and Drug Administration (FDA) had approved its popular GLP-1 anti-obesity drug Wegovy to be administered in pill form for weight loss."With today's approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection," Mike Doustdar, president and CEO of Novo Nordisk, said in a statement. The FDA had already approved a pill to be used for treating diabetes, but the new development now allows doctors to prescribe the treatment for weight loss to adults with obesity or who are overweight with at least one weight-related comorbidity, such as a heart condition, the company said.The news was welcomed by the US Obesity Care Advocacy Network (OCAN)
LAUNCESTON, Australia: Conventional wisdom in the crude oil market is that producers such as OPEC+ largely determine the price by altering output levels to achieve a desired outcome.That shibboleth was challenged in 2025 by China, which used its status as the world's biggest oil importer to provide an effective price floor and ceiling by either increasing or decreasing the volume of crude it sent to storage tanks.Production cuts in 2022 by OPEC+, which groups the Organization of the Petroleum Exporting Countries and allies led by Russia, did shore up prices. Those gains faded once it began reversing the cuts in April this year. Now, facing a looming oil glut, OPEC+ has decided to sit tight and hold production levels steady in the first quarter of next year.That leaves China to mop
